What is the timeline for an anti-peptide/protein project?

Standard delivery is 10-14 weeks. This takes you from strategy design all the way to characterized IgG leads. Note that complex antigens or extensive functional screening may extend this slightly.

What is needed to get a quote?

For a precise proposal, please share the following: The Target: Peptide sequence (w/ PTMs) or protein construct details (domains, tags, solubility). The Goal: Your primary application (e.g., Neutralization, Flow Cytometry, ELISA). Selectivity: Any required cross-reactivity or specific exclusions. Timeline: Your target deadline. Confidentiality: All sequences and project details are kept strictly confidential.

How do you ensure specificity against highly homologous proteins?

We utilize a rigorous Negative Selection (Subtractive Panning) strategy. By incubating the library with homologous "decoy" proteins first, we deplete cross-reactive binders, leaving only the clones with high specificity for your unique target epitope.

Can you handle challenging targets like PTM-specific peptides or unstable proteins?

Yes. We specialize in "difficult" targets. For unstable proteins, we employ In-Solution Panning using biotinylated antigens to preserve native conformation. For PTMs (phosphorylation, methylation, etc.), we use integrated depletion strategies with non-modified peptides to ensure absolute PTM-fidelity.

Is my project data kept confidential?

Absolutely. All sequences, structures, and project milestones are protected under strict confidentiality agreements (CDA/NDA). We prioritize the security of your intellectual property from initial inquiry to final delivery.

Peptide/Protein Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Accelerate your discovery of high-specificity, developable anti-peptide and protein antibodies. Using our ultra-diverse human libraries to deliver lead candidates in weeks, not months.

Precision Anti-Peptide & Protein Antibody Discovery

Up to 1.0×10¹¹ Diversity │ Weeks to Functional Leads │ Validated Human Frameworks │ Peptide/PTM-Specific De-risking

Discovering high-affinity, epitope-specific antibodies against peptides and proteins is notoriously challenging. Common pitfalls, from immunodominance of carrier proteins and tags to losing conformational epitopes, can derail timelines and produce non-functional candidates. Creative Biolabs's integrated service combines our deeply diverse, pre-validated human antibody libraries with peptide- and protein-optimized screening strategies. By employing rigorous decoy depletion and early developability filters, we deliver a panel of clean, downstream ready candidates with unparalleled speed and precision.

Fig.1 Peptide & Protein-Optimized Selection (Creative Biolabs AI)

Peptide & Protein-Optimized Selection
Strategies designed for linear, cyclic, and PTM-peptides plus conformational protein epitopes.

Fig.2 Carrier & Tag Decoy Depletion (Creative Biolabs AI)

Carrier & Tag Decoy Depletion
Eliminate artifact binders early for cleaner, more specific hits.

Fig.3 Developability-First by Design (Creative Biolabs AI)

Developability-First by Design
Utilize clinically validated frameworks and early liability screening to reduce downstream risk.

Fig.4 Diverse Epitope Coverage (Creative Biolabs AI)

Diverse Epitope Coverage
Maximize your chances of finding rare functional binders against your specific epitopes of interest.

Get Started / Request Your Quote Today

Workflow

1. Epitope & Antigen Strategy Design

Starts right. Maximizes on-target, epitope-faithful binding and proactively designs out carrier/tag/linker artifacts from day one.
2. Biopanning & Enrichment

Rapidly narrows diversity to a high-quality pool of specific, non-artifact binders, focusing resources on the most promising candidates.
3. Single-Clone Screening & Specificity De-risking

Eliminates costly false positives.

Systematically removes carrier/tag/linker binders and non-specific clones.
4. Functional Relevance & Epitope Strategy

Delivers candidates that work.

Ensures the selected antibodies perform robustly in your intended assay and bind the correct epitope.
5. Sequence Analytics & Liability Filtering

Informs the selection of stable, manufacturable candidates and minimizes future re-engineering cycles.
6. Expression, IgG Conversion & Developability Panel

Provides downstream-ready molecules.

Delivers application-qualified candidates for seamless transition.

Discuss Your Screening Strategy with an Expert

Quick Library Selector

Our premade libraries are built on developability-engineered frameworks, ensuring broad epitope coverage and compatibility with both phage and yeast display for peptide and protein targets.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Not sure which option fits? Request a Quote

Case Study: High-Diversity Libraries, High-Impact Outcomes

Case 1: Anti-Neurotrophic Factor Antibody

Project Goal

To discover specific antibody binders targeting a critical growth factor, utilizing a premade phage display library.

Project Challenge

Growth factors can be structurally sensitive. Traditional solid-phase panning (coating antigen on plates) risks protein denaturation, potentially leading to antibodies that bind the unfolded protein but fail to recognize the native biological target.

Our Solution

Deployed the Premade Human scFv Library with an In-Solution Panning Strategy. We utilized Biotinylated-target protein to capture binders in the liquid phase, preserving the native conformation, followed by magnetic bead retrieval.

Key Results & Data Visualization

	Enrichment Achieved significant enrichment divergence between the target group and control group after 4 rounds of panning.
	Discovery Randomly selected hundreds of clones from the enriched pool; Monoclonal Phage ELISA confirmed high-positivity rates.
	Validation Identified 3 unique sequences, converted them to Chimeric IgG format, and achieved 100% validation success (3/3) in binding assays against the target protein.

Ready to Build Your Success Story? Contact Us

Related Services

Find additional antibody discovery services tailored to your specific needs.

Fig.14 Functional human antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.15 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.16 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.17 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.18 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.19 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Fig.20 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Need something adjacent? Request a Quote

Why Partner with Creative Biolabs?

Fig.21 High-Diversity Premade Libraries (Creative Biolabs AI)

High-Diversity Premade Libraries 10¹⁰ - 10¹¹
Leverage one of the industry's largest repositories of pre-validated human antibody libraries. Our vast diversity ensures maximum epitope coverage, increasing the probability of discovering rare, high-affinity binders that traditional libraries miss.

Fig.22 Precision Epitope-Faithful Selection (Creative Biolabs AI)

Precision Epitope-Faithful Selection
Whether your target is linear, conformational, or PTM-dependent, we ensure pinpoint accuracy. By utilizing domain-aware binning and rigorous depletion strategies (using scrambled or mutant peptides), we isolate candidates that recognize the intended epitope with high fidelity.

Fig.23 Decoy-Informed Strategy: No More Artifacts (Creative Biolabs AI)

Decoy-Informed Strategy: No More Artifacts
Eliminate false positives from day one. Our multi-parameter panning strategies systematically filter out carrier-protein and tag-related binders, ensuring your leads are specific to the biological target, not the experimental construct.

Fig.24 Developability-First Engineering (Creative Biolabs AI)

Developability-First Engineering
Downstream failure is a costly risk we proactively mitigate. By utilizing clinically validated human frameworks and conducting early-stage liability triage, including polyspecificity and aggregation checks, we deliver CMC-ready candidates that minimize future re-engineering.

Fig.25 Accelerated Timelines: Weeks, Not Months (Creative Biolabs AI)

Accelerated Timelines: Weeks, Not Months
Speed is a competitive advantage. Our integrated enrichment-to-IgG conversion platform compresses traditional hit-to-lead cycles, delivering fully characterized, high-quality molecules in weeks without sacrificing scientific rigor.

Fig.26 Radical Transparency & IP Integrity (Creative Biolabs AI)

Radical Transparency & IP Integrity
Audit-Ready Data: Make go/no-go decisions with confidence via full access to NGS clonotype clustering, specificity matrices, and developability reports.

Clear Ownership: Our flexible, milestone-based models come with unambiguous IP terms, granting you full ownership and streamlining your internal procurement process.

Ready to accelerate your R&D? Request A Quote or technical consultation today. Our scientific team is ready to design a discovery campaign tailored to your specific target.

FAQ

What is the timeline for an anti-peptide/protein project?
Standard delivery is 10-14 weeks. This takes you from strategy design all the way to characterized IgG leads. Note that complex antigens or extensive functional screening may extend this slightly.
What is needed to get a quote?
For a precise proposal, please share the following:
The Target: Peptide sequence (w/ PTMs) or protein construct details (domains, tags, solubility).
The Goal: Your primary application (e.g., Neutralization, Flow Cytometry, ELISA).
Selectivity: Any required cross-reactivity or specific exclusions.
Timeline: Your target deadline.
Confidentiality: All sequences and project details are kept strictly confidential.
How do you ensure specificity against highly homologous proteins?
We utilize a rigorous Negative Selection (Subtractive Panning) strategy. By incubating the library with homologous "decoy" proteins first, we deplete cross-reactive binders, leaving only the clones with high specificity for your unique target epitope.
Can you handle challenging targets like PTM-specific peptides or unstable proteins?
Yes. We specialize in "difficult" targets. For unstable proteins, we employ In-Solution Panning using biotinylated antigens to preserve native conformation. For PTMs (phosphorylation, methylation, etc.), we use integrated depletion strategies with non-modified peptides to ensure absolute PTM-fidelity.
Is my project data kept confidential?
Absolutely. All sequences, structures, and project milestones are protected under strict confidentiality agreements (CDA/NDA). We prioritize the security of your intellectual property from initial inquiry to final delivery.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: